comparemela.com

Latest Breaking News On - Intelligent research in sight - Page 1 : comparemela.com

Intraocular Inflammation, Retinal Vascular Occlusion Infrequent in Treatment With Brolucizumab

A real-world safety study found that patients treated with brolucizumab had low occurrences of intraocular inflammation, retinal vascular occlusion, and retinal vasculitis.

United statesIntelligent research in sightAmerican academy of ophthalmologyIntelligent researchAmerican academyEarly treatmentDiabetic retinopathy study

Equity, access, and carbon cost-effectiveness of bilateral cataract surgery – Authors reply

Equity, access, and carbon cost-effectiveness of bilateral cataract surgery – Authors reply
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United statesPaulb greenbergJohnc linJohnc buchanIntelligent research in sightDarren sj tingIntelligent research

Ophthalmology Month in Review: November 2023

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our November 2023 month-in-review features a trio of FDA news, important updates to the GA pipeline, and insight into disparities in eye care.

United statesDurga borkarArshadm khananiRite aidDuke eye centerSierra eye associatesAmerican academy of ophthalmologyOcuphire pharma incKilitch healthcare indiaDrug administrationIntelligent research in sightAnnual american academyKilitch healthcare india limitedOcuphire pharmaSpecial protocol assessmentComplete response letter

Sophie Bakri, MD: Real-World Use of Faricimab in FARETINA-AMD Study

Real-world data from the FARETINA-AMD study show faricimab extended treatment intervals among eyes with nAMD.

United statesSan franciscoSophiej bakriIntelligent research in sightDrug administrationAmerican academy of ophthalmologyAnnual american academyMayo clinic

GLP-1s Don t Appear to Worsen Diabetic Retinopathy

Most patients with diabetic retinopathy who take the GLP-1 agonist semaglutide don t experience a worsening of the condition, a new study found, but they still require screening and follow-up.

United statesNew yorkZeeshan haqVaidehi dedaniaLangone healthAmerican academy of ophthalmologyIntelligent research in sightCenters for diseaseRetinal consultantsMedscape medicalAmerican academyIntelligent researchDisease controlNew york cityDiabetes mellitus type 2Iabetes mellitus type ii

vimarsana © 2020. All Rights Reserved.